BERN, SWITZERLAND / SHANGHAI, CHINA — Space Peptides today announces the appointment of Ms. Sandy Huang as President of Asia Pacific. She will lead the commercial expansion in Asia Pacific and execute the business strategy for innovative Peptide and Nucleotide drugs by accelerating the commercialization of the company’s integrated Discovery-to-commercialization services globally.
This appointment underscores Space Peptides’ commitment to making its offering for innovative drug discovery and development a core strategic pillar, empowering global clients to bring new drugs to market faster, more cost‑effectively and more reliably.
Ms. Huang brings more than 20 years of sales and business development expertise from Lonza, a global market leader in pharmaceutical CDMO, where she built China’s end-to-end biopharmaceutical commercial platform. Her outstanding capabilities in business architecture and innovative commercial models will be core drivers for the expansion of Space Peptides’ global client partnerships and strategic alliances.
Dr. Runze He, Founder, Chairman and CEO of Space Peptides, said: “We are thrilled to welcome Sandy. Her strategic perspective and network of global partners will further deepen our ‘open platform, differentiated pipeline, and integrated delivery’ model. Globalization is our firm direction, and it requires a step‑by‑step talent strategy. With Josef Schröer building our European and U.S. commercial development, Sandy now completes our Asia‑Pacific growth engine. Together, they will spearhead a global business framework spanning Europe, the Americas and Asia‑Pacific, opening a new chapter in our development.”
Ms. Sandy Huang commented: “Space Peptides’ dual‑engine model of ‘Swiss technology and Chinese manufacturing capability’ offers a rare opportunity for an innovative, truly integrated drug development approach. I look forward to building a broader network of business partnerships across Asia‑Pacific and globally — delivering value by leveraging a diverse pipeline of collaborations, partnerships, co‑developments and licensing models.”
About Space Peptides
Space Peptides is a CRDMO headquartered in Bern/Switzerland with global manufacturing assets, specializing in peptide discovery, development and manufacturing services. Committed to innovation Space Peptides’ unique AI-driven peptide discovery engine enables clients from the global Biotech and Pharmaceutical industry to explore vast areas of chemical space in order to rapidly discover new drugs with excellent conversion rates to downstream development and flexible scale‑up models from milligrams to kilograms.